Hide metadata

dc.date.accessioned2023-02-16T17:38:46Z
dc.date.available2023-02-16T17:38:46Z
dc.date.created2022-12-16T09:50:41Z
dc.date.issued2022
dc.identifier.citationSolberg, Rigmor Lunde, Ngoc Nguyen Forbord, Karl Martin Frøseth Okla, Meshail Kassem, Moustapha Jafari, Abbas . The Mammalian Cysteine Protease Legumain in Health and Disease. International Journal of Medical Sciences. 2022, 23(24), 15983
dc.identifier.urihttp://hdl.handle.net/10852/100032
dc.description.abstractThe cysteine protease legumain (also known as asparaginyl endopeptidase or δ-secretase) is the only known mammalian asparaginyl endopeptidase and is primarily localized to the endolysosomal system, although it is also found extracellularly as a secreted protein. Legumain is involved in the regulation of diverse biological processes and tissue homeostasis, and in the pathogenesis of various malignant and nonmalignant diseases. In addition to its proteolytic activity that leads to the degradation or activation of different substrates, legumain has also been shown to have a nonproteolytic ligase function. This review summarizes the current knowledge about legumain functions in health and disease, including kidney homeostasis, hematopoietic homeostasis, bone remodeling, cardiovascular and cerebrovascular diseases, fibrosis, aging and senescence, neurodegenerative diseases and cancer. In addition, this review addresses the effects of some marketed drugs on legumain. Expanding our knowledge on legumain will delineate the importance of this enzyme in regulating physiological processes and disease conditions.
dc.languageEN
dc.publisherIvyspring International Publisher
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThe Mammalian Cysteine Protease Legumain in Health and Disease
dc.title.alternativeENEngelskEnglishThe Mammalian Cysteine Protease Legumain in Health and Disease
dc.typeJournal article
dc.creator.authorSolberg, Rigmor
dc.creator.authorLunde, Ngoc Nguyen
dc.creator.authorForbord, Karl Martin Frøseth
dc.creator.authorOkla, Meshail
dc.creator.authorKassem, Moustapha
dc.creator.authorJafari, Abbas
cristin.unitcode185,15,23,30
cristin.unitnameSeksjon for farmakologi og farmasøytisk
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2094163
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International Journal of Medical Sciences&rft.volume=23&rft.spage=15983&rft.date=2022
dc.identifier.jtitleInternational Journal of Medical Sciences
dc.identifier.volume23
dc.identifier.issue24
dc.identifier.doihttps://doi.org/10.3390/ijms232415983
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1449-1907
dc.type.versionPublishedVersion
cristin.articleid15983


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International